Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 58 entries
Sorted by: Best Match Show Resources per page
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Current colorectal cancer reports

George TJ, Allegra CJ, Yothers G.
PMID: 26321890
Curr Colorectal Cancer Rep. 2015;11(5):275-280. doi: 10.1007/s11888-015-0285-2.

The conduct of clinical trials in colorectal cancer has historically relied upon endpoints such as disease-free (DFS) or overall survival (OS). While ideal, these endpoints require long-term follow-up, thus contributing to a slow pace of scientific progress in clinical...

Cite
George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11(5):275-280doi: 10.1007/s11888-015-0285-2.
George, T. J., Allegra, C. J., & Yothers, G. (2015). Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Current colorectal cancer reports, 11(5), 275-280. https://doi.org/10.1007/s11888-015-0285-2
George, Thomas J, et al. "Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials." Current colorectal cancer reports vol. 11,5 (2015): 275-280. doi: https://doi.org/10.1007/s11888-015-0285-2
George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11(5):275-280. doi: 10.1007/s11888-015-0285-2. PMID: 26321890; PMCID: PMC4550644.
Copy Download .nbib Format: NLM
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.

International journal of radiation oncology, biology, physics

Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B.
PMID: 34919884
Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):83-92. doi: 10.1016/j.ijrobp.2021.07.004.

PURPOSE: External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective trials. However, the impact on patient reported outcomes (PROs) associated with higher doses of EBRT remain poorly understood. We sought to assess the differences in...

Cite
Hall WA, Deshmukh S, Bruner DW, et al. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022;112(1):83-92doi: 10.1016/j.ijrobp.2021.07.004.
Hall, W. A., Deshmukh, S., Bruner, D. W., Michalski, J. M., Purdy, J. A., Bosch, W., Bahary, J. P., Patel, M. P., Parliament, M. B., Lock, M. I., Lau, H. Y., Souhami, L., Fisher, S. A., Kwok, Y., Seider, M. J., Vigneault, E., Rosenthal, S. A., Gustafson, G. S., Gay, H. A., Pugh, S. L., Sandler, H. M., & Movsas, B. (2022). Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. International journal of radiation oncology, biology, physics, 112(1), 83-92. https://doi.org/10.1016/j.ijrobp.2021.07.004
Hall, William A, et al. "Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126." International journal of radiation oncology, biology, physics vol. 112,1 (2022): 83-92. doi: https://doi.org/10.1016/j.ijrobp.2021.07.004
Hall WA, Deshmukh S, Bruner DW, Michalski JM, Purdy JA, Bosch W, Bahary JP, Patel MP, Parliament MB, Lock MI, Lau HY, Souhami L, Fisher SA, Kwok Y, Seider MJ, Vigneault E, Rosenthal SA, Gustafson GS, Gay HA, Pugh SL, Sandler HM, Movsas B. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):83-92. doi: 10.1016/j.ijrobp.2021.07.004. PMID: 34919884.
Copy Download .nbib Format: NLM
Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT.
PMID: 34729846
Head Neck. 2021 Nov 03; doi: 10.1002/hed.26915. Epub 2021 Nov 03.

BACKGROUND: No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC).METHODS: Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall...

Cite
Bigelow EO, Harris J, Fakhry C, et al. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021;doi: 10.1002/hed.26915.
Bigelow, E. O., Harris, J., Fakhry, C., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Frank, S. J., Nair, S. G., Bahig, H., Ridge, J. A., Caudell, J., Donaldson, C., Clifford, B. T., Shenouda, G., Birrer, M. J., Chen, Y., & Le, Q. T. (2021). Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck, . https://doi.org/10.1002/hed.26915
Bigelow, Elaine O, et al. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522." Head & neck vol. (2021). doi: https://doi.org/10.1002/hed.26915
Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021 Nov 03; doi: 10.1002/hed.26915. Epub 2021 Nov 03. PMID: 34729846.
Copy Download .nbib Format: NLM
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.

Cancers

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT.
PMID: 34207599
Cancers (Basel). 2021 Jun 09;13(12). doi: 10.3390/cancers13122882.

The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). Targeting PD1 may reverse immunosuppression induced by HNSCC and CRT....

Cite
Bauman JE, Harris J, Uppaluri R, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021;13(12)doi: 10.3390/cancers13122882.
Bauman, J. E., Harris, J., Uppaluri, R., Yao, M., Ferris, R. L., Chen, J., Jordan, R. C., Joshi, N. P., Jujjuvaparu, S., Blakaj, D. M., Henson, C., Sheqwara, J., Mell, L. K., Sen, N., Clump, D. A., Garg, M. K., Yilmaz, E., Torres-Saavedra, P., & Le, Q. T. (2021). NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers, 13(12), . https://doi.org/10.3390/cancers13122882
Bauman, Julie E, et al. "NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer." Cancers vol. 13,12 (2021). doi: https://doi.org/10.3390/cancers13122882
Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvaparu S, Blakaj DM, Henson C, Sheqwara J, Mell LK, Sen N, Clump DA, Garg MK, Yilmaz E, Torres-Saavedra P, Le QT. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021 Jun 09;13(12). doi: 10.3390/cancers13122882. PMID: 34207599; PMCID: PMC8230356.
Copy Download .nbib Format: NLM
Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck

Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT.
PMID: 34729846
Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 03.

BACKGROUND: No risk-stratification strategies exist for patients with recurrent oropharyngeal cancer (OPC).METHODS: Retrospective analysis using data from prospective NRG Oncology clinical trials RTOG 0129 and 0522. Eligibility criteria included known p16 status and smoking history, and locoregional/distant recurrence. Overall...

Cite
Bigelow EO, Harris J, Fakhry C, et al. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2021;44(1):158-167doi: 10.1002/hed.26915.
Bigelow, E. O., Harris, J., Fakhry, C., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Frank, S. J., Nair, S. G., Bahig, H., Ridge, J. A., Caudell, J., Donaldson, C., Clifford, B. T., Shenouda, G., Birrer, M. J., Chen, Y., & Le, Q. T. (2022). Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head & neck, 44(1), 158-167. https://doi.org/10.1002/hed.26915
Bigelow, Elaine O, et al. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522." Head & neck vol. 44,1 (2022): 158-167. doi: https://doi.org/10.1002/hed.26915
Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2022 Jan;44(1):158-167. doi: 10.1002/hed.26915. Epub 2021 Nov 03. PMID: 34729846.
Copy Download .nbib Format: NLM
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Journal of the National Cancer Institute

Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M.
PMID: 33729494
J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034.

BACKGROUND: There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.METHODS: Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared...

Cite
Wenzel L, Osann K, McKinney C, et al. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021;113(10):1369-1378doi: 10.1093/jnci/djab034.
Wenzel, L., Osann, K., McKinney, C., Cella, D., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., Maxwell, G. L., Mok, S. C., Conrads, T. P., Miller, A., Mannel, R. S., Gray, H. J., Hanjani, P., Huh, W. K., Spirtos, N., Leitao, M. M., Glaser, G., Sharma, S. K., Santin, A. D., Sperduto, P., Lele, S. B., Burger, R. A., Monk, B. J., & Birrer, M. (2021). Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 113(10), 1369-1378. https://doi.org/10.1093/jnci/djab034
Wenzel, Lari, et al. "Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival." Journal of the National Cancer Institute vol. 113,10 (2021): 1369-1378. doi: https://doi.org/10.1093/jnci/djab034
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034. PMID: 33729494; PMCID: PMC8486331.
Copy Download .nbib Format: NLM
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.

Journal of the National Cancer Institute

Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA.
PMID: 33159444
J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160.

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants...

Cite
Ruddy KJ, Schaid DJ, Batzler A, et al. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021;113(8):1105-1108doi: 10.1093/jnci/djaa160.
Ruddy, K. J., Schaid, D. J., Batzler, A., Cecchini, R. S., Partridge, A. H., Norman, A., Fehrenbacher, L., Stewart, E. A., Trabuco, E., Ginsburg, E., Couch, F. J., Fasching, P. A., Vachon, C., & Ganz, P. A. (2021). Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 113(8), 1105-1108. https://doi.org/10.1093/jnci/djaa160
Ruddy, Kathryn J, et al. "Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea." Journal of the National Cancer Institute vol. 113,8 (2021): 1105-1108. doi: https://doi.org/10.1093/jnci/djaa160
Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160. PMID: 33159444; PMCID: PMC8328977.
Copy Download .nbib Format: NLM
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

Gynecologic oncology

Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB.
PMID: 34903380
Gynecol Oncol. 2021 Dec 10; doi: 10.1016/j.ygyno.2021.11.021. Epub 2021 Dec 10.

INTRODUCTION: Chemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX)...

Cite
Matulonis UA, Huang HQ, Filiaci VL, et al. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecol Oncol. 2021;doi: 10.1016/j.ygyno.2021.11.021.
Matulonis, U. A., Huang, H. Q., Filiaci, V. L., Randall, M., DiSilvestro, P. A., Moxley, K. M., Fowler, J. M., Powell, M. A., Spirtos, N. M., Tewari, K. S., Richards, W. E., Nakayama, J. M., Mutch, D. G., Miller, D. S., Matei, D., & Wenzel, L. B. (2021). Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecologic oncology, . https://doi.org/10.1016/j.ygyno.2021.11.021
Matulonis, Ursula A, et al. "Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study." Gynecologic oncology vol. (2021). doi: https://doi.org/10.1016/j.ygyno.2021.11.021
Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecol Oncol. 2021 Dec 10; doi: 10.1016/j.ygyno.2021.11.021. Epub 2021 Dec 10. PMID: 34903380.
Copy Download .nbib Format: NLM
Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.

JAMA oncology

Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J.
PMID: 33885704
JAMA Oncol. 2021 Jun 01;7(6):845-852. doi: 10.1001/jamaoncol.2021.0687.

IMPORTANCE: Stereotactic body radiotherapy (SBRT) for oligometastases is hypothesized to improve survival and is increasingly used. Little evidence supports its safe use to treat patients with multiple metastases.OBJECTIVE: To establish safety of SBRT dose schedules in patients with 3...

Cite
Chmura S, Winter KA, Robinson C, et al. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021;7(6):845-852doi: 10.1001/jamaoncol.2021.0687.
Chmura, S., Winter, K. A., Robinson, C., Pisansky, T. M., Borges, V., Al-Hallaq, H., Matuszak, M., Park, S. S., Yi, S., Hasan, Y., Bazan, J., Wong, P., Yoon, H. A., Horton, J., Gan, G., Milano, M. T., Sigurdson, E. R., Moughan, J., Salama, J. K., & White, J. (2021). Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA oncology, 7(6), 845-852. https://doi.org/10.1001/jamaoncol.2021.0687
Chmura, Steve, et al. "Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial." JAMA oncology vol. 7,6 (2021): 845-852. doi: https://doi.org/10.1001/jamaoncol.2021.0687
Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Jun 01;7(6):845-852. doi: 10.1001/jamaoncol.2021.0687. PMID: 33885704; PMCID: PMC8063134.
Copy Download .nbib Format: NLM
Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey.

Contemporary clinical trials communications

Cook ED, Yeager KA, Cecchini RS, Boparai J, Brown CL, Duncan M, Cronin WM, Paskett ED.
PMID: 30023443
Contemp Clin Trials Commun. 2018 Mar 09;10:100-104. doi: 10.1016/j.conctc.2018.03.003. eCollection 2018 Jun.

INTRODUCTION: Cancer clinical trials (CCT) provide much of the evidence for clinical guidelines and standards of care. But low levels of CCT participation are well documented, especially for minorities.METHODS AND MATERIALS: We conducted an online survey of 556 recruitment...

Cite
Cook ED, Yeager KA, Cecchini RS, et al. Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. Contemp Clin Trials Commun. 2018;10:100-104doi: 10.1016/j.conctc.2018.03.003.
Cook, E. D., Yeager, K. A., Cecchini, R. S., Boparai, J., Brown, C. L., Duncan, M., Cronin, W. M., & Paskett, E. D. (2018). Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. Contemporary clinical trials communications, 10100-104. https://doi.org/10.1016/j.conctc.2018.03.003
Cook, Elise D, et al. "Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey." Contemporary clinical trials communications vol. 10 (2018): 100-104. doi: https://doi.org/10.1016/j.conctc.2018.03.003
Cook ED, Yeager KA, Cecchini RS, Boparai J, Brown CL, Duncan M, Cronin WM, Paskett ED. Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. Contemp Clin Trials Commun. 2018 Mar 09;10:100-104. doi: 10.1016/j.conctc.2018.03.003. eCollection 2018 Jun. PMID: 30023443; PMCID: PMC6046466.
Copy Download .nbib Format: NLM
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234).

Cancer

Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC.
PMID: 27419843
Cancer. 2016 Nov 15;122(22):3464-3471. doi: 10.1002/cncr.30204. Epub 2016 Jul 15.

BACKGROUND: Prospective quality metrics for neck dissection have not been established for patients with head and neck squamous cell carcinoma. The purpose of this study was to investigate the association between lymph node counts from neck dissection, local-regional recurrence,...

Cite
Divi V, Harris J, Harari PM, et al. Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer. 2016;122(22):3464-3471doi: 10.1002/cncr.30204.
Divi, V., Harris, J., Harari, P. M., Cooper, J. S., McHugh, J., Bell, D., Sturgis, E. M., Cmelak, A. J., Suntharalingam, M., Raben, D., Kim, H., Spencer, S. A., Laramore, G. E., Trotti, A., Foote, R. L., Schultz, C., Thorstad, W. L., Zhang, Q. E., Le, Q. T., & Holsinger, F. C. (2016). Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer, 122(22), 3464-3471. https://doi.org/10.1002/cncr.30204
Divi, Vasu, et al. "Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)." Cancer vol. 122,22 (2016): 3464-3471. doi: https://doi.org/10.1002/cncr.30204
Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC. Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer. 2016 Nov 15;122(22):3464-3471. doi: 10.1002/cncr.30204. Epub 2016 Jul 15. PMID: 27419843; PMCID: PMC5237619.
Copy Download .nbib Format: NLM
Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones.

Frontiers in oncology

Fountain MD, Abernathy LM, Lonardo F, Rothstein SE, Dominello MM, Yunker CK, Chen W, Gadgeel S, Joiner MC, Hillman GG.
PMID: 26557504
Front Oncol. 2015 Oct 21;5:238. doi: 10.3389/fonc.2015.00238. eCollection 2015.

INTRODUCTION: Lung cancer patients receiving radiotherapy present with acute esophagitis and chronic fibrosis, as a result of radiation injury to esophageal tissues. We have shown that soy isoflavones alleviate pneumonitis and fibrosis caused by radiation toxicity to normal lung....

Cite
Fountain MD, Abernathy LM, Lonardo F, et al. Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones. Front Oncol. 2015;5:238doi: 10.3389/fonc.2015.00238.
Fountain, M. D., Abernathy, L. M., Lonardo, F., Rothstein, S. E., Dominello, M. M., Yunker, C. K., Chen, W., Gadgeel, S., Joiner, M. C., & Hillman, G. G. (2015). Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones. Frontiers in oncology, 5238. https://doi.org/10.3389/fonc.2015.00238
Fountain, Matthew D, et al. "Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones." Frontiers in oncology vol. 5 (2015): 238. doi: https://doi.org/10.3389/fonc.2015.00238
Fountain MD, Abernathy LM, Lonardo F, Rothstein SE, Dominello MM, Yunker CK, Chen W, Gadgeel S, Joiner MC, Hillman GG. Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones. Front Oncol. 2015 Oct 21;5:238. doi: 10.3389/fonc.2015.00238. eCollection 2015. PMID: 26557504; PMCID: PMC4617099.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 58 entries